Green Health & Wellness Lilly to build $2.5 billion Germany plant as obesity drug demand soars – GWC Mag gwcmagNovember 21, 2023034 views DealsHealth 17 November 2023, 11:31 am 1 minute Reuters exclusively reported that Eli Lilly (LLY.N) will build its first plant in Germany in the western town of Alzey for 2.3 billion euros ($2.5 billion), the U.S. drugmaker said on Friday, as the sector scrambles to meet soaring demand for new diabetes and obesity therapies. Market Impact As the sector scrambles to meet demand for new diabetes and obesity therapies, the investment, confirmed by Lilly on Nov 17, will contribute to meeting surging demand for weight-loss drug Mounjaro from 2027. Eli Lilly and Danish rival Novo Nordisk (NOVOb.CO) are leading a race to seize an estimated $100 billion future global market for anti-obesity treatments. Article Tags Topics of Interest: DealsHealth Type: Reuters Best Sectors: Pharmaceuticals & HealthcareRetail & Consumer Goods Regions: Europe Countries: Germany Win Types: Exclusivity Story Types: Exclusive / Scoop Media Types: Text Customer Impact: Important Regional Story